Boston Scientific Corporation (BVMF:B1SX34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 363.92B -56.4% |
| Revenue (ttm) | 108.78B +13.5% |
| Net Income | 19.03B +46.7% |
| EPS | 12.79 +46.9% |
| Shares Out | n/a |
| PE Ratio | 19.12 |
| Forward PE | 14.74 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 22 |
| Open | 62.59 |
| Previous Close | 61.26 |
| Day's Range | 62.59 - 63.90 |
| 52-Week Range | 50.29 - 147.75 |
| Beta | 0.58 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 29, 2026 |
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatogra... [Read more]
Financial Performance
In 2025, Boston Scientific's revenue was $20.07 billion, an increase of 19.87% compared to the previous year's $16.75 billion. Earnings were $2.90 billion, an increase of 56.40%.
Financial numbers in USD Financial StatementsNews
Argus cuts Boston Scientific to Hold on growth headwinds
As previously reported, Argus downgraded Boston Scientific (BSX) to Hold from Buy. The firm notes that the company faces headwinds to growth and key product platforms, including Watchman and electroph...
Boston Scientific downgraded to Hold from Buy at Argus
Argus downgraded Boston Scientific (BSX) to Hold from Buy.
Penumbra reports Q2 EPS 88c, consensus $1.18
Reports Q2 revenue $390M, consensus $390.08M. Given the pending acquisition of Penumbra (PEN) by Boston Scientific (BSX), the company will not be providing financial guidance for the full year 2026…
Penumbra, Inc. Reports Second Quarter 2026 Financial Results
ALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026.
Boston Scientific price target lowered to $70 from $85 at RBC Capital
RBC Capital analyst Shagun Singh lowered the firm’s price target on Boston Scientific (BSX) to $70 from $85 and keeps an Outperform rating on the shares. The company reported a…
Boston Scientific price target lowered to $56 from $80 at JPMorgan
JPMorgan lowered the firm’s price target on Boston Scientific (BSX) to $56 from $80 and keeps an Overweight rating on the shares.
Boston Scientific price target lowered to $54 from $61 at BofA
BofA lowered the firm’s price target on Boston Scientific (BSX) to $54 from $61 and keeps a Buy rating on the shares. For 2027, the firm models 3% revenue growth…
Boston Scientific price target lowered to $67 from $74 at UBS
UBS lowered the firm’s price target on Boston Scientific (BSX) to $67 from $74 and keeps a Buy rating on the shares.
Boston Scientific price target lowered to $55 from $65 at Evercore ISI
Evercore ISI lowered the firm’s price target on Boston Scientific (BSX) to $55 from $65 and keeps an Outperform rating on the shares.
Boston Scientific price target lowered to $60 from $75 at Deutsche Bank
Deutsche Bank analyst Pito Chickering lowered the firm’s price target on Boston Scientific (BSX) to $60 from $75 and keeps a Buy rating on the shares.
Boston Scientific price target lowered to $56 from $64 at Baird
Baird lowered the firm’s price target on Boston Scientific (BSX) to $56 from $64 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results…
Boston Scientific price target lowered to $56 from $61 at TD Cowen
TD Cowen lowered the firm’s price target on Boston Scientific (BSX) to $56 from $61 and keeps a Buy rating on the shares. The firm said though solid 7% organic…
Boston Scientific price target lowered to $66 from $70 at Canaccord
Canaccord lowered the firm’s price target on Boston Scientific (BSX) to $66 from $70 and keeps a Buy rating on the shares. The firm said Management again cut guidance for…
Boston Scientific price target lowered to $60 from $74 at Leerink
Leerink lowered the firm’s price target on Boston Scientific (BSX) to $60 from $74 and keeps an Outperform rating on the shares.
Boston Scientific price target lowered to $50 from $55 at Wells Fargo
Wells Fargo lowered the firm’s price target on Boston Scientific (BSX) to $50 from $55 and keeps an Equal Weight rating on the shares. The firm notes reported a Q2…
Boston Scientific price target lowered to $61 from $70 at Citi
Citi analyst Joanne Wuensch lowered the firm’s price target on Boston Scientific (BSX) to $61 from $70 and keeps a Buy rating on the shares. The firm updated the company’s…
Boston Scientific price target lowered to $60 from $65 at Stifel
Stifel analyst Rick Wise lowered the firm’s price target on Boston Scientific (BSX) to $60 from $65 and keeps a Buy rating on the shares. The latest round of guidance…
Boston Scientific Earnings Call Transcript: Q2 2026
Q2 2026 saw 7% organic sales growth and 15% adjusted EPS growth, exceeding guidance. Full-year 2026 outlook was revised down due to WATCHMAN and EP headwinds, with organic revenue now expected to grow 5%-6% and adjusted EPS 7%-8%. Restructuring and new launches are set to drive recovery by 2028.
Boston Scientific Slides: Q2 2026
Boston Scientific has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 29, 2026.
Boston Scientific Earnings release: Q2 2026
Boston Scientific released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Boston Scientific Quarterly report: Q2 2026
Boston Scientific has published its Q2 2026 quarterly earnings report on July 29, 2026.
Boston Scientific Cuts Outlook Ahead of Restructuring
Boston Scientific logged higher second-quarter results and cut its full-year outlook as it begins a new restructuring plan announced earlier this week.
Boston Scientific trims annual profit forecast on softer Watchman device demand
Medical device maker Boston Scientific on Wednesday lowered its annual profit forecast, citing pressure on its Watchman heart device business.
Boston Scientific sees Q3 adjusted EPS 80c-82c, consensus 84c
Sees Q3 revenue up 3%-5%. The company said, “The company estimates net sales growth for the third quarter of 2026, versus the prior year period, to be approximately 3 to…
Boston Scientific cuts FY26 adjusted EPS view to $3.28-$3.32 from $3.34-$3.41
Consensus $3.36. Cuts FY26 revenue view to up 5.5%-6.5% from up 7%-8.5%. The company said, “The company now estimates net sales growth for the full year 2026, versus the prior…